Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Despite widespread use of statins to reduce low-density lipoprotein cholesterol (LDL-C) and associated atherosclerotic cardiovascular risk, many patients do not achieve sufficient LDL-C lowering due to muscle-related side effects, indicating novel treatment strategies are required. Bempedoic acid (ETC-1002) is a small molecule intended to lower LDL-C in hypercholesterolemic patients, and has been previously shown to modulate both ATP-citrate lyase (ACL) and AMP-activated protein kinase (AMPK) activity in rodents. However, its mechanism for LDL-C lowering, efficacy in models of atherosclerosis and relevance in humans are unknown. Here we show that ETC-1002 is a prodrug that requires activation by very long-chain acyl-CoA synthetase-1 (ACSVL1) to modulate both targets, and that inhibition of ACL leads to LDL receptor upregulation, decreased LDL-C and attenuation of atherosclerosis, independently of AMPK. Furthermore, we demonstrate that the absence of ACSVL1 in skeletal muscle provides a mechanistic basis for ETC-1002 to potentially avoid the myotoxicity associated with statin therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 ETC-1002-CoA inhibits ACL and mediates β1-selective AMPK activation. Recombinant human ACL was incubated in the presence of the indicated concentrations of ETC-1002-CoA (a–c) or ETC-1002 (d), and (a) coenzyme A (CoA), (b) citrate or (c) ATP. Conversion of [14C]-citrate to [14C]-acetyl-CoA was measured in counts per minute (CPM). Recombinant human (e) AMPKα1β1γ1 and (f) AMPKα1β2γ1 complexes were incubated in the presence of the indicated concentrations of ETC-1002, ETC-1002-CoA, AMP or A-769622. (g) Structure of ETC-1002 and the biochemical reaction that generates ETC-1002-CoA acyl-CoA synthetase (ACS). ETC-1002-CoA/CoASH enzyme ACL kinetic analyses are single measures, and representative results from n=3 independent experiments shown; AMPK activity was determined by time-resolved fluorescence resonance energy transfer expressed as mean±s.e.m. of triplicate measures. (a) Ki calculated by Michaelis–Menten kinetic analysis.](https://figures.cochat.ai/paper-figures/02df10a0267b44eda297dc9dcee13726/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-1.jpg)
![Figure 2 Differentiation of ETC-1002 from the myotoxic effects of statins. [14C]-ETC-1002 (10 μM) conversion to [14C]-ETC-1002-CoA in human liver microsomes was determined in the presence of 30 μM unlabelled (a) monocarboxylic and (b) dicarboxylic saturated competitive fatty acid substrates. RH7777 cells were treated with negative control (Control) or Slc27a2 (ACSVL1) siRNA; n=6, for 48 h, and (c) ACSVL1 expression determined by western blot, and [14C]-ETC-1002-CoA synthesis determined; n=3. (d) Both control and Slc27a2 siRNA-treated RH7777 cells were treated with vehicle, ETC-1002 (30 μM) or atorvastatin (0.5 μM), and de novo cholesterol synthesis measured over 4 h; n=6 transfections. (e) Relative ACSVL1 expression in microsomes prepared from human liver, kidney and skeletal muscle (SkM). (f) ETC-1002-CoA synthetase activity in microsomes prepared from human liver and skeletal muscle; palmitate (10 μM) used as a positive control for skeletal muscle microsome viability. (g) ACSVL1 expression was measured in primary human hepatocytes and primary human skeletal muscle (SkM) cells by western blotting and expressed relative to β-actin. (h) Primary human myotubes were treated with vehicle (Veh.), simvastatin 10 μM (Simva), atorvastatin 10 μM (Atorva) or ETC-1002 100 μM in the presence of [14C]-glucose for 12 h, and incorporation into non-saponifiable lipids determined; or treated with 0.1–100 μM simvastatin, atorvastatin or ETC-1002 for 48 h and (i) cytotoxicity was measure by GF-AFC/bis-AAF-R110 cleavage, and (j) Caspase 3,7 activity (DEVD cleavage) determined. Data for myotube cytotoxicity assays are expressed as mean±s.e.m., n=2 performed in triplicate. Data for liver (n=50 donors pooled) and kidney (n=50 donors pooled) microsome preparations are representative of two independent experiments performed in duplicate, and expressed as mean±s.d. Data for human skeletal muscle microsomes (n=4 pooled donors) are the mean±s.e.m. of two independent experiments performed in triplicate. Multiple comparisons were made using an one-way ANOVA, Bonferroni's multiple comparisons test; *P<0.05.](https://figures.cochat.ai/paper-figures/aa53cfde988849fa938e4aa3379a9671/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-2.jpg)


![Figure 5 ACL suppression increases LDLR. (a) Primary human hepatocytes were treated with vehicle or ETC-1002 (100 μM) for 18 h in the presence of [3H]-H2O or pretreated with the indicated concentrations of ETC-1002 for 1 h, following a 3 h [14C]-acetate pulse. Counts incorporated into the non-saponifiable (sterols), and saponifiable (fatty acids) lipid fractions were determined and expressed as % vehicle. (b) Primary human hepatocytes were treated with vehicle, atorvastatin (0.5 μM) or ETC-1002 (100 μM) for 36 h and total intracellular cholesterol concentrations were determined in cell lysates. (c) Media was assayed for apoB by enzyme-linked immunosorbent assay. (d) PHHs were treated with ETC-1002 for the indicated time points and the apoB concentrations were measured in the media. (e) PHH were pre-labelled overnight with [14C]-oleate and the effects of ETC-1002 treatment on oleate-derived counts in the media determined at the indicated time points. PHH hepatocytes were treated with ETC-1002 and atorvastatin, and (f) mRNA levels for HMGR, SREBF2, PCSK9 and LDLR were determined by reverse transcription–quantitative PCR or (g) LDL receptor activity determined; A-769662 (10 μM). (h) RH7777 cells were treated with the indicated concentrations of ETC-1002 or atorvastatin (0.5 μM), and [14C]-lactate incorporation into cholesterol (Chol), cholesteryl esters (CE) and triglycerides determined. (i) LDLR-mediated DiI–LDL uptake in response to the indicated concentrations of ETC-1002±atorvastatin (0.5 μM). RH7777 cells were subjected to negative control (NC) or Acly siRNA-mediated gene silencing (n=3) and analysed for (j) ACL LDLR protein levels, or (k) LDLR-mediated DiI–LDL uptake. Data for PHH are expressed as mean±s.e.m. of n=2 donors performed in triplicate (a–c,f,g; except A-769662 treatment was 1 donor) or representative of two independent experiments showing similar results (d,e). (h) IC50 and (i) EC50 determinations were made using nonlinear curve fit model. Multiple comparisons were made using (a,j,k) unpaired Student's t-test or (b,c,f,g) an one-way ANOVA, Bonferroni's multiple comparisons test; *P<0.05.](https://figures.cochat.ai/paper-figures/bdd7bd8103b34bfd9b8c72b35fad6960/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-5.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bempedoic acid is a pro-drug that reduces cholesterol synthesis by inhibiting adenosine triphosphate (ATP) citrate lyase, with very limited musculoskeletal-related side effects.280”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [280]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081 · cited 1×
“Triacsin C is a potent inhibitor of ACSL1 and 4, and a weak inhibitor of ACSVL1 (refs 43–47).”
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834 · cited 1×
“Upregulation of the LDL receptor results in a new homeostatic state, where more cellular cholesterol is derived from blood LDL particles, thus reducing blood LDL-C 51–53 .”
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
Mihaylova, M. M., & Shaw, R. J. (2011) · Nature Cell Biology · doi:10.1038/ncb2329 · Cited by 2,923
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Cited by
Items 101–200 of 499
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials
Laufs, U., Ballantyne, C. M., Banach, M., Bays, H. E., Catapano, A. L., Duell, P. B., Goldberg, A. C., Gotto, A. M., Leiter, L. A., Ray, K. K., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.03.001 · Cited by 45
Day, E. A., Ford, R. J., Lu, J. H., Lu, R., Lundenberg, L., Desjardins, E. M., Green, A. E., Lally, J., Schertzer, J. D., & Steinberg, G. R. (2020) · Biochemical Journal · doi:10.1042/bcj20200278 · Cited by 41
Self-citationJiang, Y., Wu, L., Zhu, X., Bian, H., Gao, X., & Xia, M. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02092-2 · Cited by 50
“Bempedoic acid (BemA, ETC-1002) is a liver-specific ACLY competitive inhibitor that reduces hepatic steatosis through various pathways [64].”
BackgroundGupta, Y. A., Maciorowski, D., Zak, S. E., Jones, K. A., Kathayat, R. S., Azizi, S., Mathur, R., Pearce, C. M., Ilc, D. J., Husein, H., et al. (2020) · Methods · doi:10.1016/j.ymeth.2021.01.003 · Cited by 39
Real-world utilization of bempedoic acid in an academic preventive cardiology practice
Warden, B. A., Cardiology, B.-A., Purnell, J. Q., Duell, P. B., & Fazio, S. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2021.11.013 · Cited by 39
Zhu, Z., Zhang, X., Pan, Q., Zhang, L., & Chai, J. (2023) · Liver Research · doi:10.1016/j.livres.2023.11.003 · Cited by 38
The critical issue linking lipids and inflammation: Clinical utility of stopping oxidative stress
Bale, B. F., Doneen, A. L., Leimgruber, P. P., & Vigerust, D. J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1042729 · Cited by 40
Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor
Zagelbaum, N. K., Yandrapalli, S., Nabors, C. C., & Frishman, W. H. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000218 · Cited by 43
Park, G. S. H., Jung, S., Wellen, K. E., & Jang, C. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00614-x · Cited by 39
Chasing LDL cholesterol to the bottom — PCSK9 in perspective
Libby, P., & Tokgözoğlu, L. S. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00085-x · Cited by 46
Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance
Bays, H. E., Bloedon, L. T., Lin, G., Powell, H. A., Louie, M. J., Nicholls, S. J., Lincoff, A. M., & Nissen, S. E. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.10.011 · Cited by 39
Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs
Lincoff, A. M., Ray, K. K., Sasiela, W. J., Haddad, T. M., Nicholls, S. J., Li, N., Cho, L., Mason, D., Libby, P., Goodman, S. G., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.048 · Cited by 48
A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia
Niman, S., Rana, K., Reid, J., Sheikh‐Ali, M., Lewis, T., Choksi, R. R., & Goldfaden, R. F. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00399-w · Cited by 37
“A preclinical in vivo study done by Pinkosky et al. [4] tested the efficacy and safety of bempe-doic acid in male hamsters with induced hyperlipidemia.”
Jadhav, S. B., Crass, R. L., Chapel, S. H., Kerschnitzki, M., Sasiela, W. J., Emery, M. G., Amore, B. M., Barrett, P. H. R., Watts, G. F., & Catapano, A. L. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab064 · Cited by 40
The multifaceted therapeutic value of targeting ATP-citrate lyase in atherosclerosis
Verberk, S. G. S., Kuiper, K. L., Lauterbach, M., Latz, E., & den Bossche, J. V. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.09.004 · Cited by 41
Updated Understanding of the Crosstalk Between Glucose/Insulin and Cholesterol Metabolism
Xiao, X., Luo, Y., & Peng, D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.879355 · Cited by 70
Lowering low-density lipoprotein cholesterol: from mechanisms to therapies
Luo, J., Wang, J.-K., & Song, B. (2022) · Life Metabolism · doi:10.1093/lifemeta/loac004 · Cited by 41
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Rossi, M., Fabris, E., Barbisan, D., Massa, L., & Sinagra, G. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00497-3 · Cited by 36
Yenilmez, B., Kelly, M., Zhang, G., Wetoska, N., Ilkayeva, O., Min, K., Rowland, L. A., DiMarzio, C., He, W., Raymond, N., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102401 · Cited by 39
“One possible reason for difference is that bempedoic acid treatment has been shown to induce upregulation of lowdensity lipoprotein receptor (79), which in turn would increase the uptake of lipoproteins from the circulation.”
BackgroundFixed Combination for the Treatment of Dyslipidaemia
Ferri, N., Ruscica, M., Santos, R. D., & Corsini, A. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01142-x · Cited by 40
Recent advances in synthetic pharmacotherapies for dyslipidaemias
Sirtori, C. R., Yamashita, S., Greco, M. F., Corsini, A., Watts, G. F., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319845314 · Cited by 34
“The ETC-1002 upregulated LDL receptor, decreased plasma LDL-C and attenuated experimental atherosclerosis independently of AMPK.(36) The safety and efficacy of the long-term use of bempedoic acid, including the occurrence of muscle-related adverse events, have been addressed in the following phase 3 clinical trials: C…”
InfluentialDesjardins, E. M., Wu, J., Lavoie, D. C. T., Ahmadi, E., Townsend, L. K., Morrow, M. R., Wang, D., Tsakiridis, E. E., Batchuluun, B., Fayyazi, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101193 · Cited by 33
“Bempedoic acid is a prodrug that is converted to its active moiety, bempedoyl-CoA, in the liver by the very-long-chain acyl-CoA synthetase 1 (ASCVL1).(27) This liver-targeted conversion is important to minimize muscle-related side effects, which is associated with the use of statins.”
Self-citationBrandts, J., & Ray, K. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1778668 · Cited by 33
Pharmacokinetics of bempedoic acid in patients with renal impairment
Amore, B. M., Sasiela, W. J., Ries, D. K., Tresh, P., & Emery, M. G. (2021) · Clinical and Translational Science · doi:10.1111/cts.13202 · Cited by 34
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 48
“ACLY inhibitor, which inhibits both cholesterol and fatty acids synthesis [8,9] and is also known to induce hepatic LDLR [61], is a recent addition to cholesterol-lowering therapy [42,44,62,63].”
BackgroundRole of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.964 · Cited by 39
Potential therapeutic strategies for MASH: from preclinical to clinical development
Xie, Z., Li, Y., Cheng, L., Huang, Y., Rao, W., Shi, H., & Li, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae029 · Cited by 33
Si, J., Li, J., Yu, C., Guo, Y., Bian, Z., Millwood, I. Y., Yang, L., Walters, R. G., Chen, Y., Du, H., et al. (2021) · eLife · doi:10.7554/elife.60999 · Cited by 31
Recent advance of ATP citrate lyase inhibitors for the treatment of cancer and related diseases
Liang, J.-J., Zhou, X.-F., Long, H., Li, C., Wei, J., Yu, X., Guo, Z., Zhou, Y., & Deng, Z. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106933 · Cited by 32
Etoh, K., Araki, H., Koga, T., Hino, Y., Kuribayashi, K., Hino, S., & Nakao, M. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114496 · Cited by 31
Forrestiacids C and D, unprecedented triterpene-diterpene adducts from Pseudotsuga forrestii
Zhou, P., Zang, Y., Li, C., Yuan, L., Zeng, H., Li, J. X., Hu, J., & Xiong, J. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.12.009 · Cited by 29
Human Genetics and Drug Development
Holmes, M. V. (2019) · New England Journal of Medicine · doi:10.1056/nejme1901565 · Cited by 28
Zac‐Varghese, S., Mark, P. B., Bain, S. C., Banerjee, D., Chowdhury, T. A., Dasgupta, I., De, P., Fogarty, D. G., Frankel, A., Goldet, G., et al. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03664-1 · Cited by 28
“It is a prodrug converted to bem-pedoyl-CoA by very-long-chain acyl-CoA synthetase-1, an enzyme present within the liver but absent in skeletal muscle, thus eliciting a liver specific action [22].”
BackgroundParhofer, K. G., Aguíar, C., Banach, M., Drexel, H., Gouni‐Berthold, I., de Isla, L. P., Rietzschel, E. R., Zambon, A., & Ray, K. K. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf007 · Cited by 34
“58 Its formulation as a prodrug, activated primarily in the liver, allows for action in hepatocytes but not in myocytes, with the potential to decrease the risk of SAMS compared with statin therapy.”
Steinberg, G. R. (2018) · Diabetes · doi:10.2337/dbi17-0039 · Cited by 30
“Further support for the importance of the liver AMPK-ACC signaling pathway in reducing lipogenesis and insulin resistance has also been established using small molecules that 1) directly activate AMPK b1 subunit containing heterotrimers and increase ACC phosphorylation (13,19), 2) mimic the effects of AMPK to inhibit…”
BackgroundSelf-citationMatos, A. L. D. S. A., Oakhill, J. S., Moreira, J. M. A., Loh, K., Galić, S., & Scott, J. W. (2019) · Biochemical Society Transactions · doi:10.1042/bst20180625 · Cited by 29
Mansfield, B. S., Mohamed, F., Larouche, M., & Raal, F. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144160 · Cited by 31
“Bempedoic acid is an orally administered drug that inhibits adenosine triphosphate (ATP)-citrate lyase, an enzyme located upstream of 3-hydroxy-3-methylglutaryl coenzyme A (HMG Co-A) reductase, the rate-limiting enzyme targeted by statins [31].”
BackgroundRomeo, M., Silvestrin, A., Senese, G., Nardo, F. D., Napolitano, C., Vaia, P., Coppola, A., Federico, P., Dallio, M., & Federico, A. (2025) · Biomedicines · doi:10.3390/biomedicines13082004 · Cited by 32
“The recent clinical approval of bempedoic acid for the treatment of hypercholesterolemia marks a significant therapeutic advance, offering anti-inflammatory benefits through reductions in high-sensitivity C-reactive protein (hs-CRP) levels, independently of lipid-lowering effects [177,178].”
Kumrić, M., Urlić, H., Božić, J., Vilović, M., Kurir, T. T., Glavaš, D., Miric, D., Zanchi, J., Bradarić, A., Lozo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098062 · Cited by 28
New Therapeutic Approaches for Familial Hypercholesterolemia
Ajufo, E., & Rader, D. J. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-051215-030943 · Cited by 26
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Barnard-Kelly, K. D., Battelino, T., Ceriello, A., Larsson, H. E., Fernández‐Fernández, B., Forst, T. M., Frías, J. P., Gavin, J. R., Giorgino, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02180-8 · Cited by 29
“This compound reduces cholesterol synthesis by inhibiting ATP citrate lyase, upstream of HMG-CoA reductase [54].”
BackgroundBroader Perspective on Atherosclerosis—Selected Risk Factors, Biomarkers, and Therapeutic Approach
Fularski, P., Czarnik, W., Dąbek, B., Lisińska, W., Radzioch, E., Witkowska, A., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105212 · Cited by 30
“Unlike statins, which act on HMG-CoA reductase, bempedoic acid operates upstream in the cholesterol biosynthesis pathway, offering an alternative therapeutic strategy for LDL-C reduction [108,109].”
BackgroundManaging dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 32
Stroes, E. S. G., Bays, H. E., Banach, M., Catapano, A. L., Duell, P. B., Laufs, U., Mancini, G. B. J., Ray, K. K., Sasiela, W. J., Zhang, Y., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.020 · Cited by 29
Cooke, J. P., & Lai, L. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115118 · Cited by 27
Dyslipidemia: A Narrative Review on Pharmacotherapy
de Oliveira, L. D., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L., & Soares, P. R. (2024) · Pharmaceuticals · doi:10.3390/ph17030289 · Cited by 30
“Bempedoic acid is an ATP citrate lyase (ACL) inhibitor that targets cholesterol synthesis upstream of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the enzyme inhibited by statins [59].”
BackgroundYang, Z., Lian, J., Yang, Y., Li, J., Guo, W., Lv, X., Ni, L., & Chen, Y. (2024) · Current Research in Food Science · doi:10.1016/j.crfs.2024.100964 · Cited by 28
“Evidence suggests that reducing serum LDL-C levels can decrease cardiovascular risk and play a role in preventing liver damage development (Pinkosky et al., 2016).”
Bempedoic Acid: A Promising Novel Agent for LDL-C Lowering
Agarwala, A., & Goldberg, A. C. (2020) · Future Cardiology · doi:10.2217/fca-2020-0016 · Cited by 28
Bos, M. M., Goulding, N., Lee, M. A., Hofman, A., Bot, M., Pool, R., Vijfhuizen, L. S., Zhang, X., Li, C., Mustafa, R., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-01939-0 · Cited by 22
New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia
Pirillo, A., & Catapano, A. L. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000706 · Cited by 29
SAMSON and the Nocebo Effect: Management of Statin Intolerance
Krishnamurthy, A., Bradley, C., Ascunce, R. R., & Kim, S. M. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01729-x · Cited by 25
Structure of ACLY in complex with CoA
Wei, X., & Marmorstein, R. (2019) · Worldwide Protein Data Bank · doi:10.2210/pdb6poe/pdb · Cited by 24
Ferri, N., Colombo, E., & Corsini, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111371 · Cited by 27
“The most recently approved hypocholesterolemic drug is represented by the small molecule bempedoic acid [9].”
InfluentialEmerging lipid lowering agents targeting LDL cholesterol
Wójcik, C. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1751422 · Cited by 23
Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside
Agarwala, A., Quispe, R., Goldberg, A. C., & Michos, E. D. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s251865 · Cited by 23
“Finally, the most definitive evidence of ACL inhibition as the mechanism of action was provided by Pinkosky et al.(11) Bempedoic acid is activated by very-long chain acyl-CoA synthetase-1 (ACSVL1) to produce its downstream effects of inhibiting ACL, thereby reducing visceral adiposity, proinflammatory cytokines and ch…”
BackgroundInfluentialEvaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia
Cicero, A. F. G., Fogacci, F., & Cincione, R. I. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1951222 · Cited by 27
Atualização da Diretriz Brasileira de Hipercolesterolemia Familiar – 2021
Izar, M. C. D. O., Rocha, V. Z., Bertolami, A., Santos, R. D., Lottenberg, A. M., Assad, M. H. V., Saraiva, J. F. K., Chacra, A. P. M., Martinez, T. L. D. R., Bahia, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210788 · Cited by 67
Statins and Bempedoic Acid: Different Actions of Cholesterol Inhibitors on Macrophage Activation
Linnenberger, R., Hoppstädter, J., Wrublewsky, S., Ampofo, E., & Kiemer, A. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212480 · Cited by 26
“This isozyme represents a member of the long-chain fatty-acid-coenzyme A ligase family, shows a preference for generating CoA derivatives of n-3 fatty acids [71], and is required to transform bempedoic acid into its active form [34].”
BackgroundNew Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a)
Kim, K. A., & Park, H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.37 · Cited by 23
NASH, Fibrosis and Hepatocellular Carcinoma: Lipid Synthesis and Glutamine/Acetate Signaling
Sunami, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186799 · Cited by 26
“ACSVL1 is expressed specifically in the liver of rodents and pigs, but not in the adipose tissue, intestinal muscle, or skeletal muscle [14,15].”
BackgroundBlaum, C. M., Brunner, F. J., Goßling, A., Kroeger, F., Bay, B., Lorenz, T., Graef, A., Zeller, T., Schnabel, R. B., Clemmensen, P. M., et al. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.019 · Cited by 24
KHK, PNPLA3 and PPAR as Novel Targets for the Anti-Steatotic Action of Bempedoic Acid
Velázquez, A. M., Bentanachs, R., Sala‐Vila, A., Lázaro, I., Rodríguez-Morató, J., Sánchez, R. M., Laguna, J. C., Roglans, N., & Alegret, M. (2022) · Biomedicines · doi:10.3390/biomedicines10071517 · Cited by 23
“We hypothesized that ACLY inhibition by BemA, leading to reduced fatty acid synthesis, could be a novel strategy to manage NAFLD.”
BackgroundInfluentialLiu, W., Liu, M., Xiong, H., Xia, L., Yang, Q., Chen, M., Cai, Y., & Li, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109392 · Cited by 24
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk
Theofilis, P., Vlachakis, P. K., Karakasis, P., & Kalaitzidis, R. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01290-2 · Cited by 29
“This inhibition increases LDL receptor levels and lowers LDL-C in the blood, helping to reduce atherosclerosis [43].”
Review of recent clinical trials and their impact on the treatment of hypercholesterolemia
Parham, J. S., & Goldberg, A. C. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.011 · Cited by 24
Current pharmacotherapies for atherosclerotic cardiovascular diseases
Park, J., & Oh, G. T. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01116-1 · Cited by 21
Salsalate reduces atherosclerosis through AMPKβ1 in mice
Day, E. A., Ford, R. J., Smith, B. K., Houde, V. P., Stypa, S., Rehal, S., Lhoták, Š., Kemp, B. E., Trigatti, B. L., Werstuck, G. H., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101321 · Cited by 20
Self-citationTherapeutic strategies targeting metabolic characteristics of cancer cells
Bai, R., Meng, Y., & Cui, J. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104037 · Cited by 24
Day, E. A., Townsend, L. K., Rehal, S., Batchuluun, B., Wang, D., Morrow, M. R., Lu, R., Lundenberg, L., Lu, J. H., Desjardins, E. M., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108269 · Cited by 22
Self-citationZhao, X., Ma, X.-B., Luo, X., Shi, Z., Deng, Z., Jin, Y., Xiao, Z., Tan, L., Liu, P., Jiang, S., et al. (2020) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-020-00463-w · Cited by 21
“Adenosine triphosphate-citrate lyase (ACL), a key enzyme that locates in the upstream of HMGCR in the cholesterol–biosynthesis pathway [4].”
Cross-species data integration to prioritize causal genes in lipid metabolism
Votava, J. A., & Parks, B. W. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000742 · Cited by 41
Recent advances in the management and implementation of care for familial hypercholesterolaemia
Lan, N. S. R., Bajaj, A., Watts, G. F., & Cuchel, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106857 · Cited by 22
Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
Mohamed, F., Mansfield, B. S., & Raal, F. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155082 · Cited by 22
“The enzyme ACSVL-1 is primarily expressed in the liver and kidneys and is absent in skeletal muscle [32].”
BackgroundSiculella, L., Giannotti, L., Testini, M., Gnoni, G. V., & Damiano, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041206 · Cited by 19
Arsenault, B. J., Perrot, N., & Puri, R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1110 · Cited by 21
“Conversion of bempedoic acid into its active form (bempedoic acid-CoA) in the liver by very-long chain acyl-CoA synthetase-1 (ACSVL1) appears to be a necessary step for ACLY inhibition.(65) Although”
BackgroundWan, J., Jiang, C.-X., Tang, Y., Ma, G.-L., Tong, Y., Jin, Z., Zang, Y., Osman, E. E. A., Li, J. X., Xiong, J., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105630 · Cited by 19
Metabolism-based approaches for autosomal dominant polycystic kidney disease
Bakaj, I., & Pocai, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1126055 · Cited by 22
“In animal models BA also activates AMPK (Pinkosky et al., 2016; Hallows et al., 2022) and reduces cystic growth, TKW and BUN (Hallows et al.”
BackgroundInfluentialAmore, B. M., Cramer, C. T., MacDougall, D. E., & Emery, M. G. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.001142 · Cited by 19
Bhagavathula, A. S., Matrooshi, N. O. A., Clark, C. C. T., & Rahmani, J. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00989-1 · Cited by 20
Macchi, C., Bonalume, V., Greco, M. F., Mozzo, M., Melfi, V., Sirtori, C. R., Magnaghi, V., Corsini, A., & Ruscica, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105415 · Cited by 21
“After 1 week of acclimatation, mice were fed either a HFHC (n = 15) or HFHC containing atorvastatin (n = 15) (350 mg/kg of diet per 4 g per daily food intake; Mucedola, Milan, Italy) [54] for further 12 weeks [55].”
MethodHussain, A., & Ballantyne, C. M. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-100119-013612 · Cited by 22
SLC16A7 Promotes Triglyceride Deposition by De Novo Lipogenesis in Chicken Muscle Tissue
Wang, Y., Liu, L., Liu, X., Tan, X., Zhu, Y., Luo, N., Zhao, G., Cui, H., & Wen, J. (2022) · Biology · doi:10.3390/biology11111547 · Cited by 18
Beneficial effects of bempedoic acid treatment in polycystic kidney disease cells and mice
Hallows, K. R., Li, H., Saitta, B., Sepehr, S. H., Huang, P., Pham, J., Wang, J., Mancino, V., Chung, E. J., Pinkosky, S. L., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1001941 · Cited by 20
“The pro-drug BA gets converted to its active form (BA-CoA) via Very Long-Chain Acyl-CoA Synthetase (ACSVL1; a.k.a. FATP2), whose long isoform is only substantially expressed in liver and kidney tissues (Pinkosky et al., 2016, Steinberg et al., 1999).”
BackgroundResultSelf-citationWang, K., Han, L., Tan, Y., Hong, H., Fan, H., & Luo, Y. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c09092 · Cited by 21
Zhou, P., Huang, T., Ma, G., Tong, Y., Chen, W., Zang, Y., Xiong, J., Li, J. X., & Hu, J. (2023) · Journal of Natural Products · doi:10.1021/acs.jnatprod.3c00040 · Cited by 17
Zhang, L., Hu, W., Qiu, Z., Li, Z., & Bian, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00179 · Cited by 17
Mutschlechner, D., Tscharre, M., Huber, K., & Gremmel, T. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad052 · Cited by 20
Colivicchi, F., Fusco, S. A. D., Scicchitano, P., Caldarola, P., Murrone, A., Valente, S., Urbinati, S., Roncon, L., Amodeo, V., Aspromonte, N., et al. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001108 · Cited by 24
“(2010)(15) Male mice with knocked down hepatic ACYL expression Mice fed a low-fat o for 25 days Pinkosky et al. (2013)(13) Hamster model of hyperlipidemia Hamsters fed a hig cholesterol diet 30 mg/kg/day of bempedoic acid weeks Filippov et al. (2013)(17) Cultured rat hepatocytes and primary human monocytederived macro…”
MethodInfluentialBurger, A. L., Pogran, E., Muthspiel, M., Kaufmann, C. C., Jäger, B., & Huber, K. (2022) · Biomedicines · doi:10.3390/biomedicines10050970 · Cited by 17
“Reduced intracellular cholesterol synthesis in the hepatocytes and subsequently upregulated LDL-C receptor expression with increased LDLC plasma clearance leads to significant lipid-lowering properties of bempedoic acid [49] The CLEAR study program of randomized, placebo-controlled trials tested the efficacy and safet…”
BackgroundMethodInfluentialGoyal, A., Changez, M. I. K., Tariq, M. D., Mushtaq, F., Shamim, U., Sohail, A. H., & Mahalwar, G. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102236 · Cited by 18
Management of dyslipidemia in coronary artery disease: the present and the future
Dimitriadis, K. S., Theofilis, P., Iliakis, P., Pyrpyris, N., Dri, E., Sakalidis, A., Σουλαϊδόπουλος, Σ., Tsioufis, P., Fragkoulis, C., Chrysohoou, C. A., et al. (2024) · Coronary Artery Disease · doi:10.1097/mca.0000000000001375 · Cited by 22
“[24].”
LDL-Cholesterol-Lowering Therapy
Pirillo, A., Norata, G. D., & Catapano, A. L. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_361 · Cited by 18
Ahmed, A. A., Mohamed, S. K., Nofal, S., Morsy, E. M. E., & Ahmed, A. A. E. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121573 · Cited by 16
Gupta, K., Balachandran, I., Foy, J., Hermel, M., Latif, A., Krittanawong, C., Slipczuk, L. N., Baloch, F., Samad, Z. Z., & Virani, S. S. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01103-4 · Cited by 14
Bempedoic Acid: Lipid Lowering for Cardiovascular Disease Prevention
Albosta, M. S., Grant, J. K., & Michos, E. D. (2023) · Heart International · doi:10.17925/hi.2023.17.2.1 · Cited by 21
“20 This enzyme is present in hepatocytes and not present in skeletal muscle cells, therefore allowing for targeted uptake by the liver ( Figure 2 ).”
BackgroundMethodInfluentialDuell, P. B., Banach, M., Catapano, A. L., Laufs, U., Mancini, G. B. J., Ray, K. K., Broestl, C., Zhang, Y., Lei, L., & Goldberg, A. C. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.12.005 · Cited by 21
LeBlond, N. D., Ghorbani, P., O’Dwyer, C., Ambursley, N., Nunes, J. R. C., Smith, T. K. T., Trzaskalski, N. A., Mulvihill, E. E., Viollet, B., Foretz, M., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120001040 · Cited by 16
Bempedoic Acid: A New Non-statin Drug for the Treatment of Dyslipidemia
Wichaiyo, S., & Supharattanasitthi, W. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01075-w · Cited by 17
“Moreover, bempedoic acid exhibits a 20% reduction in the progression of atherosclerosis in apolipoprotein E-deficient mice fed a high-fat diet, an atherosclerosis model [18].”
BackgroundMethodInfluentialEngel, B. J., Preusch, K., Brown, C., Cramer, C. T., & Shoup, R. E. (2020) · Journal of Chromatography B · doi:10.1016/j.jchromb.2020.122291 · Cited by 19
Bempedoic Acid for Lowering LDL Cholesterol
Honigberg, M. C., & Natarajan, P. (2019) · JAMA · doi:10.1001/jama.2019.16598 · Cited by 16
Metadata
- Authors
- Pinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., Steinberg, G. R., & Lalwani, N. D.
- Affiliations
- Esperion Therapeutics (United States) (US)
- McMaster University (CA)
- St. Joseph’s Healthcare Hamilton (CA)
- Corresponding author
- Pinkosky, Stephen L.
- Steinberg, Gregory R.
- Venue
- Nature Communications
- Published
- 2016-11-28
- Volume
- 7
- Issue
- 1
- Pages
- 13457-13457
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5133702
- OpenAlex
- W2558991743
- Cited by
- 498
- References
- 73
- Citations by year
- 2026: 63 · 2025: 50 · 2024: 76 · 2023: 79 · 2022: 55 · 2021: 67 · 2020: 50 · 2019: 24 · 2018: 21 · 2017: 10 · 2016: 1
- FWCI
- 21.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Funders
- Amgen
- Heart and Stroke Foundation of Canada
- McMaster University
- Esperion Therapeutics
- Amgen Canada
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- bempedoic acid, ATP citrate lyase, LDL cholesterol lowering, atherosclerosis, prodrug activation, LDL receptor upregulation, AMPK, hypercholesterolemia, skeletal muscle
- MeSH terms
- Adenylate Kinase, Animals, ATP Citrate (pro-S)-Lyase, Dicarboxylic Acids, Enzyme Activation, Enzyme Inhibitors, Fatty Acids, Humans, Cholesterol, LDL, Liver, Mice, Inbred C57BL, Models, Biological, Organ Specificity, Receptors, LDL, Up-Regulation, Mice, Knockout, Disease Progression, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hepatocytes, Atherosclerosis, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.